产品
编 号：F333895
分子式：C23H23ClN2O5S
分子量：474.96
分子式：C23H23ClN2O5S
分子量：474.96
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 355025-24-0
产品详情
生物活性：
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK. Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells.
体内研究：
Ki16425 (Debio 0719) (1-30 mg/kg; i.p.; at 30 min prior to LPA injection) inhibits LPA-induced neuropathic pain-like behaviors.Animal Model:20-24 g male standard ddY-strain mice
Dosage:1-30 mg/kg
Administration:Intraperitoneal injection; at 30 minutes prior to LPA injection
Result:LPA-induced neuropathic pain behaviors were attenuated in a dose-dependent manner.
体外研究：
Ki16425 (10 μM; 1.5 hours; HEK293A cells) treatment blocks LPA-induced dephosphorylation of YAP/TAZ in HEK293A cells. Ki16425 partially inhibits the ability of serum to repress YAP/TAZ phosphorylation, particularly at low serum concentrations (0.2%).
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK. Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells.
体内研究：
Ki16425 (Debio 0719) (1-30 mg/kg; i.p.; at 30 min prior to LPA injection) inhibits LPA-induced neuropathic pain-like behaviors.Animal Model:20-24 g male standard ddY-strain mice
Dosage:1-30 mg/kg
Administration:Intraperitoneal injection; at 30 minutes prior to LPA injection
Result:LPA-induced neuropathic pain behaviors were attenuated in a dose-dependent manner.
体外研究：
Ki16425 (10 μM; 1.5 hours; HEK293A cells) treatment blocks LPA-induced dephosphorylation of YAP/TAZ in HEK293A cells. Ki16425 partially inhibits the ability of serum to repress YAP/TAZ phosphorylation, particularly at low serum concentrations (0.2%).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备